TY - JOUR
T1 - Oral immunotherapy for peanut allergy
T2 - Multipractice experience with epinephrine-treated reactions
AU - Wasserman, Richard L.
AU - Factor, Jeffrey M.
AU - Baker, James W.
AU - Mansfield, Lyndon E.
AU - Katz, Yitzhak
AU - Hague, Angela R.
AU - Paul, Marianne M.
AU - Sugerman, Robert W.
AU - Lee, Jason O.
AU - Lester, Mitchell R.
AU - Mendelson, Louis M.
AU - Nacshon, Liat
AU - Levy, Michael B.
AU - Goldberg, Michael R.
AU - Elizur, Arnon
N1 - Funding Information:
Patient data collection and analysis were supported by each participating allergy practice, without external funding.
PY - 2014/1
Y1 - 2014/1
N2 - Background: Peanut allergy creates the risk of life-threatening anaphylaxis that can disrupt psychosocial development and family life. The avoidance management strategy often fails to prevent anaphylaxis and may contribute to social dysfunction. Peanut oral immunotherapy may address these problems, but there are safety concerns regarding implementation in clinical practice. Objective: The purpose of this report is to communicate observations about the frequency of epinephrine-treated reactions during peanut oral immunotherapy in 5 different allergy/immunology practices. Methods: Retrospective chart review of peanut oral immunotherapy performed in 5 clinical allergy practices. Results: A total of 352 treated patients received 240,351 doses of peanut, peanut butter, or peanut flour, and experienced 95 reactions that were treated with epinephrine. Only 3 patients received 2 doses of epinephrine, and no patient required more intensive treatment. A total of 298 patients achieved the target maintenance dose for a success rate of 85%. Conclusion: Peanut oral immunotherapy carries a risk of systemic reactions. In the context of oral immunotherapy, those reactions were recognized and treated promptly. Peanut oral immunotherapy may be a suitable therapy for patients managed by qualified allergists/immunologists.
AB - Background: Peanut allergy creates the risk of life-threatening anaphylaxis that can disrupt psychosocial development and family life. The avoidance management strategy often fails to prevent anaphylaxis and may contribute to social dysfunction. Peanut oral immunotherapy may address these problems, but there are safety concerns regarding implementation in clinical practice. Objective: The purpose of this report is to communicate observations about the frequency of epinephrine-treated reactions during peanut oral immunotherapy in 5 different allergy/immunology practices. Methods: Retrospective chart review of peanut oral immunotherapy performed in 5 clinical allergy practices. Results: A total of 352 treated patients received 240,351 doses of peanut, peanut butter, or peanut flour, and experienced 95 reactions that were treated with epinephrine. Only 3 patients received 2 doses of epinephrine, and no patient required more intensive treatment. A total of 298 patients achieved the target maintenance dose for a success rate of 85%. Conclusion: Peanut oral immunotherapy carries a risk of systemic reactions. In the context of oral immunotherapy, those reactions were recognized and treated promptly. Peanut oral immunotherapy may be a suitable therapy for patients managed by qualified allergists/immunologists.
KW - Food allergy
KW - Food allergy treatment
KW - Oral immunotherapy
KW - Peanut
UR - http://www.scopus.com/inward/record.url?scp=84891648438&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2013.10.001
DO - 10.1016/j.jaip.2013.10.001
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84891648438
SN - 2213-2198
VL - 2
SP - 91-96.e2
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 1
ER -